secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0001104659-25-031099
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax says FDA missed PDUFA deadline for COVID-19 vaccine BLA; still awaiting decision
--------------------------------------------------------------------------------

- FDA's April 1 PDUFA date passed; no official decision received as of April 2, 2025.
- Novavax completed all FDA information requests and believes BLA is ready for approval.
- Phase 3 data cited showing vaccine is safe and effective for COVID-19 prevention.
- Company positions its vaccine as an attractive alternative to mRNA COVID-19 vaccines in U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925031099/0001104659-25-031099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925031099/tm2511339d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-031099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer